You are not logged in

Salix Q4 Net Loss Narrows

 
Salix Pharmaceuticals has reported a net loss of $7.02m, or $0.13 per diluted share, for the fourth quarter ended December 31, 2009, compared to $11.07m, or $0.23 per diluted share, for the comparable period in 2008.

The company has posted net product revenues of $70.22m for the fourth quarter of 2009, an increase of 16 percent, compared to $60.56m, for the same period in 2008.

For the full year ended December 31, 2009, the company has posted a net loss of $43.62m, or $0.88 per diluted share, compared to $47.6m, or $0.99 per diluted share, for the year ago period. Net product revenues were $232.89m for the 12 months, compared to $178.76m for the year ago period.

Carolyn Logan, president and CEO of the company, said: “2009 was one of the most exciting and rewarding years in the company’s history to date as we continued to achieve success in both the commercial and product development areas of our business.

“We look forward to continued growth and expansion during 2010 and beyond. We plan to continue to execute our business strategy by in-licensing late-stage and marketed products, developing the products in our pipeline and ensuring that our marketed products are provided with the attention and support required to achieve success.”

Will the company further reduce net loss in 2010?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.

User Comments

Name *
Enter code   
Submit Comment

  Login


Copyright ©2010 Progressive Innovations Ltd. Reproduction of material from any page on this domain without prior written permission is strictly prohibited.
 
Show Bar